Many Multiple Myelomas: Making More of the Molecular Mayhem

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

(2011) G. J. Morgan et al.   BLOOD

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

(2011) N. C. Munshi et al.   BLOOD

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

(2011) W-J Chng et al.   LEUKEMIA

MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites

(2011) Huadong Pei et al.   NATURE

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Pathogenesis of Monoclonal Gammopathy of Undetermined Significance and Progression to Multiple Myeloma

(2011) Adriana Zingone et al.   SEMINARS IN HEMATOLOGY

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

(2010) H. Avet-Loiseau et al.   BLOOD

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

(2010) B. Nair et al.   BLOOD

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

(2010) T. Steinbrunn et al.   BLOOD

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

(2010) B. Hoang et al.   BLOOD

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

(2010) A. Broyl et al.   BLOOD

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

(2010) B. A. Walker et al.   BLOOD

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells

(2010) E. Martinez-Garcia et al.   BLOOD

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development

(2010) Flavia Pichiorri et al.   CANCER CELL

The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance

(2010) F. M. Ross et al.   HAEMATOLOGICA

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

(2010) L. Lode et al.   HAEMATOLOGICA

Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma

(2010) T. Rasmussen et al.   HAEMATOLOGICA

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

(2010) D. Hose et al.   HAEMATOLOGICA

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

(2010) Maria-Victoria Mateos et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study

(2010) Angela Dispenzieri et al.   LANCET

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

(2010) María-Victoria Mateos et al.   LANCET ONCOLOGY

Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms

(2010) A Zingone et al.   LEUKEMIA

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

(2010) H Avet-Loiseau et al.   LEUKEMIA

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

(2009) P. Kapoor et al.   BLOOD

A monoclonal gammopathy precedes multiple myeloma in most patients

(2009) B. M. Weiss et al.   BLOOD

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

(2009) O. Landgren et al.   BLOOD

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study

(2009) J-F Rossi et al.   BRITISH JOURNAL OF CANCER

Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12∼23 amplicon

(2009) Jeffrey R. Sawyer et al.   BRITISH JOURNAL OF HAEMATOLOGY

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

(2009) Jing Qing et al.   JOURNAL OF CLINICAL INVESTIGATION

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

(2009) Shaji K. Kumar et al.   MAYO CLINIC PROCEEDINGS

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

(2008) B. Barlogie et al.   BLOOD

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

(2008) Mauricio Pineda-Roman et al.   BRITISH JOURNAL OF HAEMATOLOGY

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

(2008) Marta Chesi et al.   CANCER CELL

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome

(2008) Olivier Decaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical and biological significance of RAS mutations in multiple myeloma

(2008) W J Chng et al.   LEUKEMIA

Genetic aberrations and survival in plasma cell leukemia

(2008) R E Tiedemann et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE

The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor

(2007) J. Marango et al.   BLOOD